EIDOS TM is a CE-IVDD certified solution that uses AI to select patients for immunotherapy, a relatively new treatment method for cancer. The solution is one of the results of the strategic partnership for the use of AI in cancer treatments that Ellogon entered into in 2020 with the Netherlands Cancer Institute (NKI). EIDOS TM is not only effective, but also easy and seamless to integrate into clinical practice.
Determine chances of success faster
“Unfortunately, immunotherapy is not effective for everyone,” explains Robert Kuipers, CEO of Ellogon. “Results are currently lacking in approximately 50% of patients receiving immunotherapy, while the therapy would probably be beneficial for approximately 15% of non-selected patients. Our solution helps to determine the chance of success of immunotherapy for a patient more accurately. This increases the chance of survival for the patient and makes it easier to keep healthcare costs under control. In concrete terms, our solution leads to a total annual saving of €500 million and for the EU member states even €13 billion.
Ellogon: affordable care for everyone
Immunotherapy is currently still very expensive: costs vary from 50,000 to 200,000 euros per patient. The demand for affordable cancer treatments is growing rapidly; the number of cancer cases is expected to increase by 70% in the next twenty years. “ROM InWest invests in Ellogon because with EIDOS TM they make it possible for patients who benefit from immunotherapy to actually receive this treatment,” explains Janet Nieboer CEO of ROM InWest ROM InWest. “This makes it a good example of how digitalization can keep healthcare accessible and affordable for everyone.”
Immunotherapy popular
Immunotherapy uses the patient's immune system to attack cancer cells in the body, with the aim of preventing the spread of cancer, keeping the cancer under control or eliminating it altogether. It is so popular because the chance of overall survival is three times higher than with traditional treatments. Many Dutch hospitals now prescribe immunotherapy.
